Compare Futu Holdings Ltd (FUTU) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Natera Inc. Common Stock — how do they compare? Futu Holdings Ltd trades at $107.3 (market cap $15.99B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.6× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.28% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Natera Inc. Common Stock for 0 Days on average.
| FUTU | NTRA | |
|---|---|---|
Market Cap | $15.99B | $57.03B |
Volume | 931,065 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $199.04 | $425.64 |
52-Week Low | $89.76 | $179.42 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $16.33B | $56.18B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $109.45, down 2.5% today, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong profitability with a 42.92% net income margin and 30.8% ROE, while valuation ratios like a P/E of 11.38 suggest potential undervaluation. Recent news highlights expansion efforts, such as Moomoo's partnership with X's Cashtag program, but also ongoing securities class action lawsuits.
The outlook is cautiously optimistic, supported by robust fundamentals and analyst consensus pointing to a 33% upside, though risks from legal challenges and market volatility persist. Revenue growth remains a key catalyst, but investors should weigh the high institutional ownership against regulatory and competitive pressures.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
